Quince Therapeutics Inc (QNCX) has a current Price-to-Book (P/B) ratio of 154.38. Compared to its 3-year average P/B ratio of 13.50, the current P/B ratio is approximately 1043.50% higher. Relative to its 5-year average P/B ratio of 9.84, the current P/B ratio is about 1469.66% higher. Quince Therapeutics Inc (QNCX) has a Forward Free Cash Flow (FCF) yield of approximately -23.33%. Compared to its 3-year average FCF yield of -53.48%, the current FCF yield is approximately -56.37% lower. Relative to its 5-year average FCF yield of -56.44%, the current FCF yield is about -58.66% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for QNCX competitors is 1.77, providing a benchmark for relative valuation. Quince Therapeutics Inc Corp (QNCX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of QNCX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of QNCX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is QNCX currently overvalued or undervalued?

What is Quince Therapeutics Inc (QNCX) fair value?

QNCX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Quince Therapeutics Inc (QNCX) is between to according to relative valuation method.

How does QNCX's valuation metrics compare to the industry average?

The average P/S ratio for QNCX's competitors is 1.77, providing a benchmark for relative valuation. Quince Therapeutics Inc Corp (QNCX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Quince Therapeutics Inc (QNCX) as of Mar 03 2026?

As of Mar 03 2026, Quince Therapeutics Inc (QNCX) has a P/B ratio of 154.38. This indicates that the market values QNCX at 154.38 times its book value.

What is the current FCF Yield for Quince Therapeutics Inc (QNCX) as of Mar 03 2026?

As of Mar 03 2026, Quince Therapeutics Inc (QNCX) has a FCF Yield of -23.33%. This means that for every dollar of Quince Therapeutics Inc's market capitalization, the company generates -23.33 cents in free cash flow.

What is the current Forward P/E ratio for Quince Therapeutics Inc (QNCX) as of Mar 03 2026?

As of Mar 03 2026, Quince Therapeutics Inc (QNCX) has a Forward P/E ratio of -4.01. This means the market is willing to pay $-4.01 for every dollar of Quince Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Quince Therapeutics Inc (QNCX) as of Mar 03 2026?

As of Mar 03 2026, Quince Therapeutics Inc (QNCX) has a Forward P/S ratio of 0.00. This means the market is valuing QNCX at $0.00 for every dollar of expected revenue over the next 12 months.

QNCX Valuation